1 p. l., p. 185-314. illus., plates. 25 cm.Bibliography: p. 313-314

Foekens, John

Geurts-Moespot, Anneke

Grebenchtchikov, Nicolai

Klijn, Jan

Kwast, Theo

Look, Maxime

Meijer van Gelder, Marion

Peters, Harry

Sweep, C.G.

Lowie, Robert Harry, 1883-1957.

American Museum of Natural History Scientific Publications

Notes on Shoshonean ethnography. Anthropological papers of the AMNH ;  v. 20, pt. 3.

Item does not contain fulltextVascular endothelial growth factor (VEGF), a potent angiogenic factor, has been reported to be associated with a poor prognosis in primary breast cancer and in several other cancer types. In the present study, we have measured with ELISA the levels of VEGF in cytosolic extracts of 845 primary breast tumors of patients who developed a recurrence during follow-up. All of the patients received tamoxifen (n = 618) or cyclophosphamide, methotrexate, 5-fluorouracil (CMF) or 5-fluorouracil, Adriamycin, cyclophosphamide (FAC) chemotherapy (n = 227) as first-line systemic therapy after diagnosis of advanced disease. VEGF levels were not related to age or menopausal status but were negatively related to the cytosolic levels of estrogen receptor and progesterone receptor (P < 0.0001). In patients who relapsed within 1 year after primary surgery, tumor VEGF levels were higher than in patients who showed a longer disease-free interval (P = 0.0005). In patients with a first relapse in the viscera, VEGF levels were higher compared with those that relapsed to the bone or soft tissue (P = 0.0004). In univariate analysis for response to first-line tamoxifen therapy, patients with high or intermediate levels showed a poor rate of response, compared with patients with low tumor-VEGF levels (P = 0.0001). Similarly, in multivariate analysis for response to tamoxifen treatment, corrected for age, site of relapse, disease-free interval, and estrogen receptor and progesterone receptor status, VEGF status was an independent predictive factor (P = 0.009). In concordance, higher levels of VEGF were associated with a short progression-free survival and postrelapse overall survival (both, P < 0.0001). On first-line chemotherapy, the rate of response decreased with higher tumor levels of VEGF, both in univariate (P = 0.003) and in multivariate analysis (P = 0.004). Furthermore, higher VEGF levels were associated with a short progression-free survival (P = 0.003) and postrelapse overall survival (P = 0.001). In conclusion, the tumor VEGF level is an important independent marker that predicts a poor efficacy of both tamoxifen and chemotherapy in advanced breast cancer. Knowledge of the tumor level of VEGF might be helpful in selecting individual patients who may benefit from treatments with antiangiogenic agents combined with conventionally used drugs

Foekens, J.A.

Peters, H.A.

Grebenchtchikov, N.J.

Look, M.P.

Meijer-van Gelder, M.E.

Geurts-Moespot, A.

Kwast, T.H. van der

Sweep, C.G.J.

Klijn, J.G.M.

Radboud Repository

High tumor levels of vascular endothelial growth factor predict poor response to systemic therapy in advanced breast cancer.

Vascular endothelial growth factor (VEGF), a potent angiogenic factor, has been reported to be associated with a poor prognosis in primary breast cancer and in several other cancer types. In the present study, we have measured with ELISA the levels of VEGF in cytosolic extracts of 845 primary breast tumors of patients who developed a recurrence during follow-up. All of the patients received tamoxifen (n = 618) or cyclophosphamide, methotrexate, 5-fluorouracil (CMF) or 5-fluorouracil, Adriamycin, cyclophosphamide (FAC) chemotherapy (n = 227) as first-line systemic therapy after diagnosis of advanced disease. VEGF levels were not related to age or menopausal status but were negatively related to the cytosolic levels of estrogen receptor and progesterone receptor (P < 0.0001). In patients who relapsed within 1 year after primary surgery, tumor VEGF levels were higher than in patients who showed a longer disease-free interval (P = 0.0005). In patients with a first relapse in the viscera, VEGF levels were higher compared with those that relapsed to the bone or soft tissue (P = 0.0004). In univariate analysis for response to first-line tamoxifen therapy, patients with high or intermediate levels showed a poor rate of response, compared with patients with low tumor-VEGF levels (P = 0.0001). Similarly, in multivariate analysis for response to tamoxifen treatment, corrected for age, site of relapse, disease-free interval, and estrogen receptor and progesterone receptor status, VEGF status was an independent predictive factor (P = 0.009). In concordance, higher levels of VEGF were associated with a short progression-free survival and postrelapse overall survival (both, P < 0.0001). On first-line chemotherapy, the rate of response decreased with higher tumor levels of VEGF, both in univariate (P = 0.003) and in multivariate analysis (P = 0.004). Furthermore, higher VEGF levels were associated with a short progression-free survival (P = 0.003) and postrelapse overall survival (P = 0.001). In conclusion, the tumor VEGF level is an important independent marker that predicts a poor efficacy of both tamoxifen and chemotherapy in advanced breast cancer. Knowledge of the tumor level of VEGF might be helpful in selecting individual patients who may benefit from treatments with antiangiogenic agents combined with conventionally used drugs

NARCIS 

Vascular endothelial growth factor (VEGF), a potent angiogenic factor, has been reported to be associated with a poor prognosis in primary breast cancer and in several other cancer types. In the present study, we have measured with ELISA the levels of VEGF in cytosolic extracts of 845 primary breast tumors of patients who developed a recurrence during follow-up. All of the patients received tamoxifen (n 5 618) or cyclophos-phamide, methotrexate, 5-fluorouracil (CMF) or 5-fluorouracil, Adria-mycin, cyclophosphamide (FAC) chemotherapy (n 5 227) as first-line systemic therapy after diagnosis of advanced disease. VEGF levels were not related to age or menopausal status but were negatively related to the cytosolic levels of estrogen receptor and progesterone receptor (P &lt; 0.0001). In patients who relapsed within 1 year after primary surgery, tumor VEGF levels were higher than in patients who showed a longer disease-free interval (P 5 0.0005). In patients with a first relapse i

John A. Foekens

Harry A. Peters

Nicolai Grebenchtchikov

Maxime P. Look

Marion E. Meijer-van Gelder

Anneke Geurts-moespot

Theo H. Van Der Kwast

Jan G. M. Klijn

CiteSeerX

High tumor levels of vascular endothelial growth factor predict poor response to systemic therapy in advanced breast cancer

Peters, HAAM (Harry)

Grebenchtchikov, N

Meijer - Gelder, M

Geurts-Moespot, A

Kwast, Theodorus

Sweep, CGJ

EUR Research Repository

English

Vascular endothelial growth factor (VEGF), a potent angiogenic factor, has

          been reported to be associated with a poor prognosis in primary breast

          cancer and in several other cancer types. In the present study, we have

          measured with ELISA the levels of VEGF in cytosolic extracts of 845

          primary breast tumors of patients who developed a recurrence during

          follow-up. All of the patients received tamoxifen (n = 618) or

          cyclophosphamide, methotrexate, 5-fluorouracil (CMF) or 5-fluorouracil,

          Adriamycin, cyclophosphamide (FAC) chemotherapy (n = 227) as first-line

          systemic therapy after diagnosis of advanced disease. VEGF levels were not

          related to age or menopausal status but were negatively related to the

          cytosolic levels of estrogen receptor and progesterone receptor (P <

          0.0001). In patients who relapsed within 1 year after primary surgery,

          tumor VEGF levels were higher than in patients who showed a longer

          disease-free interval (P = 0.0005). In patients with a first relapse in

          the viscera, VEGF levels were higher compared with those that relapsed to

          the bone or soft tissue (P = 0.0004). In univariate analysis for response

          to first-line tamoxifen therapy, patients with high or intermediate levels

          showed a poor rate of response, compared with patients with low tumor-VEGF

          levels (P = 0.0001). Similarly, in multivariate analysis for response to

          tamoxifen treatment, corrected for age, site of relapse, disease-free

          interval, and estrogen receptor and progesterone receptor status, VEGF

          status was an independent predictive factor (P = 0.009). In concordance,

          higher levels of VEGF were associated with a short progression-free

          survival and postrelapse overall survival (both, P < 0.0001). On

          first-line chemotherapy, the rate of response decreased with higher tumor

          levels of VEGF, both in univariate (P = 0.003) and in multivariate

          analysis (P = 0.004). Furthermore, higher VEGF levels were associated with

          a short progression-free survival (P = 0.003) and postrelapse overall

          survival (P = 0.001). In conclusion, the tumor VEGF level is an important

          independent marker that predicts a poor efficacy of both tamoxifen and

          chemotherapy in advanced breast cancer. Knowledge of the tumor level of

          VEGF might be helpful in selecting individual patients who may benefit

          from treatments with antiangiogenic agents combined with conventionally

          used drugs

Notes on Shoshonean ethnography. Anthropological papers of the AMNH ; v. 20, pt. 3.

Abstract

Similar works

Full text

Available Versions

American Museum of Natural History Scientific Publications

Radboud Repository

NARCIS

CiteSeerX

NARCIS

EUR Research Repository

EUR Research Repository

Erasmus University Digital Repository